{"title":"关于专家讨论 TRIANGLE 研究结果的决议","authors":"","doi":"10.26442/18151434.2023.4.202535","DOIUrl":null,"url":null,"abstract":"On September 30, 2023, a discussion of the results of the European Community study on mantle cell lymphoma – TRIANGLE study was held in Moscow. The TRIANGLE phase III international randomized trial enrolled nearly 900 young subjects (up to 65 years of age) with histologically confirmed untreated mantle cell lymphoma in advanced stages II–IV. Study centers from 14 European countries participated in the study. According to the TRIANGLE study results, adding ibrutinib to autologous hematopoietic stem cell transplantation allows achieving a 3-year disease-free survival rate of 88%, which is significantly better than in the standard chemotherapy group.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"1 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resolution on the experts' discussion of the TRIANGLE study results\",\"authors\":\"\",\"doi\":\"10.26442/18151434.2023.4.202535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"On September 30, 2023, a discussion of the results of the European Community study on mantle cell lymphoma – TRIANGLE study was held in Moscow. The TRIANGLE phase III international randomized trial enrolled nearly 900 young subjects (up to 65 years of age) with histologically confirmed untreated mantle cell lymphoma in advanced stages II–IV. Study centers from 14 European countries participated in the study. According to the TRIANGLE study results, adding ibrutinib to autologous hematopoietic stem cell transplantation allows achieving a 3-year disease-free survival rate of 88%, which is significantly better than in the standard chemotherapy group.\",\"PeriodicalId\":16401,\"journal\":{\"name\":\"Journal of Modern Oncology\",\"volume\":\"1 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Modern Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.26442/18151434.2023.4.202535\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Modern Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/18151434.2023.4.202535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Resolution on the experts' discussion of the TRIANGLE study results
On September 30, 2023, a discussion of the results of the European Community study on mantle cell lymphoma – TRIANGLE study was held in Moscow. The TRIANGLE phase III international randomized trial enrolled nearly 900 young subjects (up to 65 years of age) with histologically confirmed untreated mantle cell lymphoma in advanced stages II–IV. Study centers from 14 European countries participated in the study. According to the TRIANGLE study results, adding ibrutinib to autologous hematopoietic stem cell transplantation allows achieving a 3-year disease-free survival rate of 88%, which is significantly better than in the standard chemotherapy group.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
